Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Wilmington, DE.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
16
Frequently Asked Questions
What is Market Cap of Inhibikase Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Inhibikase Therapeutics Inc market cap is $116.25M.
What is the 52-week high for Inhibikase Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Inhibikase Therapeutics Inc 52 week high is $4.20 as of September 13, 2025.
What is the 52-week low for Inhibikase Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Inhibikase Therapeutics Inc 52 week low is $1.12 as of September 13, 2025.
What is Inhibikase Therapeutics Inc stock price today?
Inhibikase Therapeutics Inc stock price today is $1.56.
What was Inhibikase Therapeutics Inc stock price yesterday?
Inhibikase Therapeutics Inc stock price yesterday was $1.68.
What is the PE ratio of Inhibikase Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Inhibikase Therapeutics Inc’s P/E ratio is -1.43.
What is the Price-to-Book ratio of Inhibikase Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Inhibikase Therapeutics Inc P/B ratio is 1.4521.
What is the 50-day moving average of Inhibikase Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Inhibikase Therapeutics Inc 50-day moving average is $1.76.
How many employess does Inhibikase Therapeutics Inc has?
